The prevalence of LUTS seems to be similar in women and men [3] , with nocturia being the most prevalent symptom (48.6% in men; 54.5% in women). The prevalence of storage LUTS (51.3% in men; 59.2% in women) was greater than that of voiding (25.7% in men; 19 .5% in women) and postmicturition (16.9% in men; 14.2% in women) symptoms combined [3] . In women, LUTS are usually equal to overactive bladder (oAB) syndrome and are assumed to be caused by detrusor overactivity (Do), even if this does not always appear to be the case [4] [5] [6] [7] . Irwin et al. (2006) studied 19,000 adult men and women and confirmed that oAB is not solely a female disorder. They found that the prevalence in both sexes is around 12% and that the rate increases with age. They also found that the prevalence of storage LUTS (suggestive of oAB) was twice as common in men as voiding LUTS.
Available information thus suggests that LUTS are a group of non-sex-specific and non-organ-specific symptoms, which are sometimes age-related and progressive. A broader clinical perspective has been advocated: all LUTS should be treated, not just selected symptoms [8] .
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Concerning pathophysiology of storage symptoms in men, focus has shifted from the prostate to the bladder as the source of some of the LUTS and as the therapeutic target [9] [10] [11] . This has created a renewed interest in oAB drugs for treatment of male LUTS and has opened the door for new combinations of drugs. Such combinations are being evaluated in clinical trials [12] [13] [14] [15] and seem to be increasingly prescribed "off label" by physicians. Still, there is a need for more effective treatments.
Since the pathophysiology of LUTS/oAB is multifactorial [16] , there are many potential targets for future drugs, as identified in preclinical investigations [17, 18] . However, it is difficult to predict what principles can be applied clinically. The mere finding that a drug affects the LUT in a desirable direction seldom motivates speculations like "this may be a new way of treating LUTS/oAB". For several of the potentially useful drugs, published clinical studies have demonstrated the proof of principle. This review will discuss the pharmacology of and clinical experiences with some of these drugs.
SUBTyPE SELECTIVE α 1 -ADRENoCEPToR ANTAGoNISTS
Currently used α 1 -adrenoceptor (AR) antagonists are effective for treatment of both storage and voiding LUTS associated with or suggestive of BPH [19, 20] . However, in females with oAB, α1-AR antagonists seem to be ineffective. In a randomized controlled trial (RCT) comprising 364 women with oAB, no effect of tamsulosin versus placebo could be demonstrated [21] . on the other hand, voiding symptoms in women with functional outflow obstruction or LUTS were successfully treated with an α 1 -AR antagonist [22, 23] .
A previous studies had shown that targeting the predominant α 1 -AR (α 1 A/L) in the prostate did not result in more effective drugs [28] . However, silodosin (KD-3213), which has a high selectivity for α 1 A number of β 3 -AR selective agonists are currently being evaluated as potential treatment for oAB in humans including GW427353 and yM178 [61] . Takasu et al. (2007) reported that the selective β 3 -AR agonist, yM187, mediated muscle relaxation in human bladder strips. reported the results of a controlled clinical trial with this drug in patients with oAB. Tolterodine and placebo served as controls. The primary efficacy analysis showed a statistically significant reduction in mean micturition frequency compared to placebo. With respect to secondary variables, yM178 was significantly superior to placebo concerning mean volume voided per micturition, mean number of incontinence episodes, nocturia episodes, urgency incontinence episodes, and urgency episodes per 24 hours. The drug was well tolerated, and the most commonly reported side effects were headache and gastrointestinal adverse effects. The results of this well conducted proof of concept study showed that the principle of β 3 -AR agonism may be useful for treatment of patients with oAB. However, to show that this class of drugs offers a viable therapeutic alternative or complement to current treatment of LUTS/oAB requires further well designed RCTs.
PHoSPHoDIESTERASE (PDE) INHIBIToRS
Drugs stimulating the generation of cAMP are known to relax smooth muscles, including the detrusor [40, 64] . It is also well established that drugs acting through the No/cGMP system can relax the smooth muscle of the bladder outflow region [40] . Use of PDE inhibitors to enhance the presumed cAMP-and cGMP-mediated relaxation of LUT smooth muscles (detrusor prostate, urethra) should then be a logical approach [33] . There are presently 11 families of PDEs, some of which preferentially hydrolyse either cAMP or cGMP [33] .
As a basis for PDE inhibitor treatment of LUTS, Uckert et al. (2001) investigated human bladder tissue, revealing messenger RNA for PDEs 1A, 1B, 2A, 4A, 4B, 5A, 7A, 8A, and 9A; most of these PDEs preferably inhibit the breakdown of cAMP. In vitro, human detrusor muscle responded poorly to sodium nitroprusside and to agents acting via the cGMP system [66] . However, significant relaxation of human detrusor muscle, paralleled by increases in cyclic nucleotide levels, was induced by papaverine, vinpocetine (a low affinity inhibitor of PDE 1), and forskolin (stimulating the generation of cAMP), suggesting that the cAMP pathway and PDE 1 may be important in regulation of detrusor smooth muscle tone [67] . Significant dose-dependent relaxations were also induced by human cAMP analogs [67] . With these studies as a background, Truss et al. (2000) presented preliminary clinical data with vinpocetine in patients with urgency, urgency incontinence, or low compliance bladders not responding to standard antimuscarinic therapy. This initial open pilot study suggested a possible role for vinpocetine in the treatment of oAB. However, the results of a larger RCT in patients with Do showed that vinpocetine only showed statistically significant results for one parameter [67] . Studies with PDE 1 inhibitors other than vinpocetin (which may not be an optimal drug for elucidating the principle) do not seem to have been performed.
PDE 4 (which also preferably hydrolyses cAMP) has been implicated in the control of bladder smooth muscle tone. PDE 4 inhibitors reduced the in vitro contractile response of guinea pig [68] and rat [69, 70] bladder strips and also suppressed rhythmic bladder contractions of the isolated guinea pig bladder [71] . Previous experiences with selective PDE 4 inhibitors showed emesis to be a dose-limiting effect [72] . If this side action can be avoided, PDE 4 inhibition seems to be a promising approach.
No has been demonstrated to be an important inhibitory neurotransmitter in the smooth muscle of the urethra and its relaxant effect is associated with increased levels of cyclic GMP [73] . However, few investigations have addressed the cAMP-and cGMP-mediated signal transduction pathways and its key enzymes in the mammalian urethra. Morita et al. (2000) examined the effects of isoproterenol, prostaglandin E1 and E2, and SNP on the contractile force and tissue content of cAMP and cGMP in the rabbit urethra. They concluded that both cyclic nucleotides can produce relaxation of the urethra. The distribution of PDEs in the male urethral structures does not seem to have been studied.
The observation that patients treated for erectile dysfunction with PDE 5 inhibitors had an improvement of their LUTS has sparked a new interest in using these drugs for treatment of LUTS and oAB. After the report in an open study that treatment with sildenafil appeared to improve urinary symptom scores in men with ED and LUTS [75] , this observation has been confirmed in several well designed and conducted RCTs [77, 78] . In a well designed RCT, treatment with tadalafil once daily, in addition to improving erectile function in men with LUTS, was demonstrated to produce a clinically meaningful and statistically significant symptomatic improvement of LUTS [77] .
In another RCT, vardenafil given twice daily for eight weeks to men with ED and LUTS and was shown to significantly improve LUTS, erectile function, and quality of life [78] .
The mechanism behind the beneficial effect of the PDE inhibitors on LUTS/oAB and their site(s) of action largely remain to be elucidated. If the site of action were the smooth muscles of the outflow region (and the effect relaxation), an increase in flow rate should be expected. In the trials referred to, no such effect was found. However, there are several other structures in the LUT that may be involved, including those in the urothelial signaling pathway (urothelium, interstitial cells, and suburothelial afferent nerves).
VITAMAN D 3 RECEPToR ANALoGUES
Rat and human bladders were shown to express receptors for vitamin D [79] , which makes it conceivable that the bladder may also be a target for vitamin D. Analogues of vitamin D3 have also been shown to inhibit BPH cell proliferation and to counteract the mitogenic activity of potent growth factors for BPH cells [80] [81] [82] . Experiments in rats with bladder outflow obstruction showed that one of the analogues, BXL-628, at non-hypercalcemic doses did not prevent bladder hypertrophy but reduced the damage to the bladder smooth muscle, which occurs with increasing bladder weight [83] . The mechanism of action for the effects has not been clarified. However, elocalcitol was shown to have an inhibitory effect on the RhoA/Rho kinase pathway [84] . Upregulation of this pathway has been associated with bladder changes associated with diabetes, outflow obstruction, and Do [85, 86] . volume greater than or equal to 40 ml [87] . In a RCT enrolling 120 female patients with oAB where the primary endpoint was an increase in the mean volume voided, a significant increase was demonstrated versus placebo [88] . Whether or not vitamin D receptor agonism (monotherapy or in combination) will be a useful alternative for the treatment of LUTS/oAB requires further RCTs.
GoNADoTRoPIN-RELEASING HoRMoNE ANTAGoNISTS
The beneficial effects of the 5a-reductase inhibitors (5-ARIs) finasteride and dutasteride in the treatment of male LUTS are well documented. The efficacy of other hormonal treatments, for example antiandrogens or gonadotropin-releasing hormone (GNRH; also known as luteinizing hormone-releasing hormone: LHRH) agonists, is either poor or at the expense of unacceptable side effects, such as medical castration associated with hot flashes, decrease of potency and libido, and negative effects on bone density following long-term androgen ablation [89] [90] [91] [92] . With LHRH antagonists submaximal, non-castrating blockade of the androgen testosterone and consequently of dihydrotestosterone (DHT) can be achieved, thus avoiding medical castration. Debruyne et al. (2008) demonstrated in a two phase RCT that the LHRH antagonist cetrorelix, given subcutaneously weekly for 20 weeks to 140 men with LUTS (IPSS > 13, peak urinary flow rates 5-13 ml/s), rapidly caused a significant improvement in the mean IPSS: the peak decrease was -5.4 to -5.9 vs -2.8 for placebo. All dosage regimens tested were well tolerated, and the authors concluded that the drug offered a safe and effective treatment of male LUTS. Further studies are needed to assess whether or not this therapeutic principle is a useful addition to the current treatment alternatives.
CENTRALLy ACTING DRUGS
Many parts of the brain seem to be activated during storage and voiding [94] [95] [96] , and there is increasing interest in drugs modulating the micturition reflex by a central action [96] . Several drugs used for pain treatment also affect micturition; morphine and some antiepileptic drugs being a few examples. However, central nervous mechanisms so far have not been preferred targets for drugs aimed at treating OAB, since selective actions may be difficult to obtain. Holstege, reviewing some of the central mechnisms involved in micturition, including the periaqueductal gray (PAG) and the pontine micturition center (PMC), suggested that "the problem in OAB or urgency-incontinence is at the level of the PAG or PMC and their connections, and possible treatments for this condition should target the micturition pathways at that level."
GABAPENTIN
Gabapentin is one of the new first-generation antiepileptic drugs that expanded its use into a broad range of neurologic and psychiatric disorders [98] . It was originally designed as an anticonvulsant GABA (y-aminobutyric acid) mimeticly capable of crossing the blood-brain barrier [99] . The effects of gabapentin, however, do not appear to be mediated through interaction with GABA receptors, and its mechanism of action remains controversial [99] . It has been suggested that it acts by binding to a subunit of the α2δ unit of voltage-dependent calcium channels [98, 100] . Gabapentin is also widely used not only for seizures and neuropathic pain, but for many other indications, such as anxiety and sleep disorders, because of its apparent lack of toxicity.
Carbone et al. (2006) reported on the effect of gabapentin on neurogenic DO. They found a positive effect on symptoms and significant improvement in urodynamic parameters, and suggested that the effects of the drug should be explored in further controlled studies in both neurogenic and nonneurogenic DO. Kim et al. (2004) studied the effects of gabapentin in patients with OAB and nocturia not responding to antimuscarinics. They found that 14 out of 31 patients improved with oral gabapentin. The drug was generally well tolerated, and the authors suggested that it can be considered in selective patients when conventional modalities have failed. It is possible that gabapentin and other α2δ ligands (e.g., pregabalin and analogs) will offer new therapeutic alternatives.
TRAMADoL
Tramadol is a well-known analgesic drug [103] . By itself, it is a weak µ-receptor agonist, but it is metabolized to several different compounds, some of them almost as effective as morphine at the µ-receptor. However, the drug (metabolites) also inhibits serotonin (5-HT) and noradrenaline reuptake [103] . This profile is of particular interest, since both μ-receptor agonism and amine reuptake inhibition may be useful principles for treatment of LUTS/OAB/DO, as shown in a placobo controlled study with duloxetine [104] .
In rats, tramadol abolished experimentally induced DO caused by cerebral infarction [105] . Tramadol also inhibited DO induced by apomorphine in rats [106 
NK1-RECEPToR ANTAGoNISTS
The main endogenous tachykinins (substance P (SP), neurokinin A (NKA) and neurokinin B (NKB)) and their preferred receptors (NK1, NK2, and NK3) have been demonstrated in various CNS regions, including those involved in micturition control [109] [110] [111] . NK1 receptor expressing neurons in the dorsal horn of the spinal cord may play an important role in DO, and tachykinin involvement via NK1 receptors in the micturition reflex induced by bladder filling has been demonstrated in both normal rats and more clearly in rats with bladder hypertrophy secondary to BOO [112] . Capsaicin-induced detrusor overactivity was reduced by blocking NK1 receptor-expressing neurons in the spinal cord by using the intrathecally-administered substance P-saponin conjugate [113] . Furthermore, blockade of spinal NK1 receptor could suppress detrusor activity induced by dopamine receptor (L-DOPA) stimulation [114] .
In conscious rats undergoing continuous cystometry, antagonists of both NK1 and NK2 receptors inhibited micturition, decreasing micturition pressure and increasing bladder capacity at low doses, and inducing dribbling incontinence at high doses. This was most conspicuous in animals with outflow obstruction [115] . Intracerebroventricular administration of NK1 and NK2 receptor antagonists were used to awake rats' suppressed detrusor activity induced by dopamine receptor (L-DOPA) stimulation [116] . Taken together, available information suggests that spinal and supraspinal NK1 and NK2 receptors may be involved in micturition control.
Aprepitant, an NK-1 receptor antagonist used for treatment of chemotherapy-induced nausea and vomiting [117] significantly improved symptoms of OAB in postmenopausal women with a history of urgency incontinence or mixed incontinence (with predominantly urgency urinary incontinence), as shown in a well designed pilot RCT [118] . The primary end point was percent change from baseline in average daily micturitions assessed by a voiding diary. Secondary end points included average daily total urinary incontinence and urgency incontinence episodes, and urgency episodes. Aprepitant significantly decreased the average daily number of micturitions compared with placebo at 8 weeks. The average daily number of urgency episodes was also significantly reduced compared to placebo, and so were the average daily number of urgency incontinence and total urinary incontinence episodes, although the difference was not statistically significant. Aprepitant was generally well tolerated and the incidence of side effects, including dry mouth, was low. The results of this initial proof of concept study suggest that NK-1 receptor antagonism holds promise as a potential treatment approach for OAB.
ALTERNATIVE STRATEGIES -CoMBINATIoNS
Combining the current α 1 -adrenoceptor antagonists with other agents might theoretically provide improved symptom relief. One such example is the combination of α 1 -adrenoceptor antagonists with five alpha reductase inhibitors, which has proven to improve clinical outcomes and reduce the incidence of BPH and LUTS progression measured as symptom worsening, retention or progression to surgery [119, 120] . Other combinations have also been tested with varying degrees of success. Traditionally muscarinic receptor antagonists have been contradicted in patients with BPH due to fears of urinary retention. However, this dogma has been questioned and several studies have been performed in which α 1 -adrenoceptor antagonists are combined with muscarinic receptor antagonists with promising results [12, 13, 15, 77, [121] [122] [123] [124] . Speculatively, several other combinations can be suggested [125] .
FUTURE DIRECTIoNS
Botulinum toxin A and the vanilloid receptor agonists capsaicin and resiniferatoxin are principles with good evidence (RCTs) of therapeutic effect in OAB/DO [17] . Botulinum toxin A, although not approved for use in OAB/DO in most countries, has a well documented therapeutic effect in neurogenic detrusor overactivity, and it may also be useful for IDO. It has largely replaced the vanilloids as therapeutic alternatives UroToday International Journal ® state of the art review in patients not responding to antimuscarinic treatment. The endocannabinoid system has received widespread attention as a pharmacotherapeutic target to modulate physiological and pathophysiological conditions also in the bladder. Hiragata et al. (2007) showed that ajulemic acid, a mixed CB1/CB2 receptor agonist, can suppress normal bladder activity and urinary frequency induced by bladder nociceptive stimuli. These inhibitory effects were inhibited by AM251, a selective CB1 receptor antagonist. These findings suggest that cannabinoid receptor agonists may have a potential as therapeutic agents in DO.
An exciting finding is that TRPV1 receptor antagonists have potentially useful effects on micturition in animal models [126] . Two other TRPs may also have a role in bladder function. TRPA1 receptors were shown to be expressed in C-fiber afferents as well as urothelium and interstitial cells, both in the bladder and urethra, and also to affect micturition [127] [128] [129] . Of interest is the finding that hydrogen sulfide, which may be formed endogenously during infection/inflammation, is an activator of TRPA1. Another member of the TRP family, the TRPV4 receptor (channel), can be activated by hypo-osmolarity, heat, or certain lipid compounds and seems to be expressed mainly by urothelial cells. In mice, deletion of this channel results in impaired voiding responses [130] , and intravesical instillation of a TRPV4 agonist in the rat triggered a novel voiding reflex, which could regulate the late phase of contraction [131] . In the conscious ewe, TRPV4 may also be involved in a urethra to bladder reflex, proposed to facilitate bladder emptying [132] . The roles of TRPA1 and TRPV4 in the normal and pathological bladder have to be established. Whether or not antagonists of these receptors could be potential targets for drugs aimed for treatment of LUTS/OAB/DO can only be speculated on.
CoNCLUSIoNS
There UI J
